HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Zacks Rank    Equity Research    Obama Stocks    My Account    Help    
FREE winning picks
Quote:
Login
Search:

Commentary BETA - Give us your feedback
Analyst Blog

GSK Boosts Theravance, Near-Term

By: Grant Zeng, CFA
June 26, 2008 | Comments: 0
Recommended this article (0)
THRX | GSK
Print    Share

We expect the U.S. launch of Theravance, Inc.’s (THRX - Analyst Report) Telavancin, for the treatment of complicated skin infections, to occur by August, provided the company satisfactorily deals with the manufacturing issues and site monitoring and conduct concerns raised by the U.S. Food and Drug Administration. However, given the stiff competition in the complicated skin and skin structure infections and the hospital-acquired pneumonia markets, we expect only $185 million in Telavancin sales in 2011.

The company’s new financial restructuring program will result in annual cost savings of $17 million. However, we are more excited about the company’s Beyond Advair collaboration with GlaxoSmithKline (GSK - Analyst Report). The deal holds significant value for the company and could eventually drive the company to profitability.

Theravance has a deep pipeline of exciting, late-stage compounds. However, approval of one or more of the compounds under the collaboration is not expected before 2011. Hence, we maintain our Hold rating on Theravance. We arrive at our target price of $15 by applying a P/S multiple of 15.4x to our 2011 revenue figure of $105.2 million, discounted at 20 percent for 3 years.

Varun Parwal contributed to this report.

Read the full analyst report on THRX

Read the full analyst report on GSK


Email

Print

Share

RSS

Rate Pos

Rate Neg

Comment
Read/Post Comments (0) | Recommended this article (0)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
Be the first to comment on this article!

More Zacks Resources

Market Summary Jul 04, 2009 11:40 am ET
DJIA 8280.74  -223.32 -2.63%
NASD 1796.52  -49.20 -2.67%
S&P 500 896.42  -26.91 -2.91%
Sponsored Links
Commentary Beta
GIVE US YOUR FEEDBACK